AU2017227515B2 - Imatinib for use in the treatment of stroke - Google Patents

Imatinib for use in the treatment of stroke Download PDF

Info

Publication number
AU2017227515B2
AU2017227515B2 AU2017227515A AU2017227515A AU2017227515B2 AU 2017227515 B2 AU2017227515 B2 AU 2017227515B2 AU 2017227515 A AU2017227515 A AU 2017227515A AU 2017227515 A AU2017227515 A AU 2017227515A AU 2017227515 B2 AU2017227515 B2 AU 2017227515B2
Authority
AU
Australia
Prior art keywords
imatinib
day
dose
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017227515A
Other languages
English (en)
Other versions
AU2017227515A1 (en
Inventor
Ulf Eriksson
Nils Gunnar WAHLGREN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brain Consultant Nils Gunnar Wahlgren AB
Hamra Invest AB
Original Assignee
Brain Consultant Nils Gunnar Wahlgren AB
Hamra Invest AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brain Consultant Nils Gunnar Wahlgren AB, Hamra Invest AB filed Critical Brain Consultant Nils Gunnar Wahlgren AB
Publication of AU2017227515A1 publication Critical patent/AU2017227515A1/en
Application granted granted Critical
Publication of AU2017227515B2 publication Critical patent/AU2017227515B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017227515A 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke Active AU2017227515B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1650260A SE539450C2 (en) 2016-02-29 2016-02-29 Imatinib for use in the treatment of stroke
SE1650260-1 2016-02-29
PCT/SE2017/050183 WO2017151043A1 (en) 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke

Publications (2)

Publication Number Publication Date
AU2017227515A1 AU2017227515A1 (en) 2018-08-30
AU2017227515B2 true AU2017227515B2 (en) 2022-03-24

Family

ID=59744327

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017227515A Active AU2017227515B2 (en) 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke

Country Status (17)

Country Link
US (2) US10953010B2 (enExample)
EP (1) EP3423060B1 (enExample)
JP (1) JP6914957B2 (enExample)
CN (2) CN119523986A (enExample)
AU (1) AU2017227515B2 (enExample)
DK (1) DK3423060T3 (enExample)
ES (1) ES2895432T3 (enExample)
HR (1) HRP20211621T1 (enExample)
HU (1) HUE056798T2 (enExample)
LT (1) LT3423060T (enExample)
PL (1) PL3423060T3 (enExample)
PT (1) PT3423060T (enExample)
RS (1) RS62465B1 (enExample)
RU (1) RU2739382C1 (enExample)
SE (1) SE539450C2 (enExample)
SI (1) SI3423060T1 (enExample)
WO (1) WO2017151043A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
CN114306342B (zh) * 2020-09-30 2024-06-28 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法
US20230279120A1 (en) * 2021-11-09 2023-09-07 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
EP4311539A1 (en) 2022-07-29 2024-01-31 Artorange Ltd. Imatinib formulation for parenteral administration
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121941A2 (en) * 2005-05-10 2006-11-16 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007240429A1 (en) * 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Ltd Methods and compositions for modulation of blood-neural barrier
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
KR20090061055A (ko) * 2006-10-26 2009-06-15 시코르, 인크. 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
TR201911199T4 (tr) * 2009-03-27 2019-08-21 Moleac Pte Ltd Hücre büyümesini arttırmak için tedavi.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121941A2 (en) * 2005-05-10 2006-11-16 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant

Also Published As

Publication number Publication date
HUE056798T2 (hu) 2022-03-28
EP3423060A4 (en) 2020-01-01
HRP20211621T1 (hr) 2022-02-04
PL3423060T3 (pl) 2022-01-10
JP2019507165A (ja) 2019-03-14
US10953010B2 (en) 2021-03-23
SE1650260A1 (en) 2017-08-30
US20190030030A1 (en) 2019-01-31
US20210236488A1 (en) 2021-08-05
PT3423060T (pt) 2021-10-20
LT3423060T (lt) 2021-11-10
CN108697711A (zh) 2018-10-23
SI3423060T1 (sl) 2021-11-30
JP6914957B2 (ja) 2021-08-04
CN119523986A (zh) 2025-02-28
WO2017151043A1 (en) 2017-09-08
RU2739382C1 (ru) 2020-12-23
DK3423060T3 (da) 2021-10-25
ES2895432T3 (es) 2022-02-21
SE539450C2 (en) 2017-09-26
AU2017227515A1 (en) 2018-08-30
EP3423060A1 (en) 2019-01-09
EP3423060B1 (en) 2021-07-21
RS62465B1 (sr) 2021-11-30

Similar Documents

Publication Publication Date Title
US20210236488A1 (en) Imatinib for use in the treatment of stroke
Diringer et al. Aneurysmal subarachnoid hemorrhage: strategies for preventing vasospasm in the intensive care unit
Naoulou et al. Efficacy of tranexamic acid in the treatment of idiopathic and non‐functional heavy menstrual bleeding: a systematic review
JP2023053274A (ja) Ｃｎｓ浮腫に関連する損傷または状態を処置する方法
JP2015522630A (ja) 多発性硬化症治療のためのビオチンの使用
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
JP2024523559A (ja) アルドステロン合成酵素阻害剤を使用する方法
Awad et al. Dabigatran, intracranial hemorrhage, and the neurosurgeon
JP2025502266A (ja) 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法
US20250099465A1 (en) Remibrutinib for use in the treatment of hidradenitis suppurativa
JP6042886B2 (ja) 早漏症治療用の薬学組成物
Chen et al. Propafenone-associated gross hematuria: a case report and review of the literature
RU2845317C1 (ru) Способ лечения постковидного синдрома
KR20190134825A (ko) 수축력 저하 수반성 배뇨근 과활동 개선제
RU2821032C1 (ru) Способы лечения заболеваний, связанных с рецептором s1p1
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradol
ALLAM WCN23-0127 KIDNEY OUT COMES IN SUDANSES CHILDREN WITH LUPUS NEPHRITIES
Palau et al. Neuro-ophthalmology annual review
TW202342049A (zh) 治療患有腦損傷的患者的方法以及增加患有腦損傷的患者的擴展版格拉斯哥結局量表的值的方法
US20180243247A1 (en) Drug combinations for cerebrovascular disease
TW202400145A (zh) 治療ｓ１ｐ受體相關病況之方法
Song et al. Hemoptysis due to Aspirin Treatment Alternative to Warfarin Therapy in a Patient with Atrial Fibrillation
Katayoun Vahedi Surgery for acute ischemic stroke
Tarpley Oxprenolol Hydrochloride: A Long‐Term Study of Efficacy, Safety, and Tolerability
Appelboom¹ et al. for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)